Meeting
2022 ASCO Annual Meeting
Sequential pembrolizumab (pembro) and chemotherapy (chemo) in newly diagnosed, early unfavorable, or advanced-stage classical Hodgkin lymphoma (cHL): The phase 2 KEYNOTE-C11 study.
Authors
Jane N. Winter
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
Jane N. Winter , Akash Nahar , Eunhee Kim , Patricia Marinello
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT05008224
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS7584)
DOI
10.1200/JCO.2022.40.16_suppl.TPS7584
Abstract #
TPS7584
Poster Bd #
233b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.
First Author: Christine Mauz-Körholz
Poster
2018 ASCO Annual Meeting
KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.
First Author: Christine Mauz-Korholz
Poster
2023 ASCO Annual Meeting
Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.
First Author: Luciana Vinti
Poster
2018 ASCO Annual Meeting
Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.
First Author: David J. Straus